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Abstract: Liver stiffness (LS), assessed using transient elastography
(TE), and (FIB-4) can both estimate the risk of developing hepatocel-
lular carcinoma (HCC). We compared prognostic performances of LS
and FIB-4 to predict HCC development in patients with chronic
hepatitis B (CHB).
Data from 1308 patients with CHB, who underwent TE, were
retrospectively analyzed. FIB-4 was calculated for all patients. The
cumulative rate of HCC development was assessed using Kaplan–Meier
curves. The predictive performances of LS and FIB-4 were evaluated
using time-dependent receiver-operating characteristic (ROC) curves.
The mean age (883 men) was 50 years. During follow-up (median
6.1 years), 119 patients developed HCC. The areas under the ROC
curves (AUROCs) predicting HCC risk at 3, 5, and 7 years were
consistently greater for LS than for FIB-4 (0.791–0.807 vs 0.691–
0.725; all P< 0.05). Similarly, when the respective AUROCs for LS and
FIB-4 at every time point during the 7-year follow-up were plotted, LS
also showed consistently better performance than FIB-4 after 1 year of
enrollment. The combined use of LS and FIB-4 significantly enhanced
the prognostic performance compared with the use of FIB-4 alone
(P< 0.05), but the performance of the combined scores was statistically
similar to that of LS alone (P> 0.05).
LS showed significantly better performance than FIB-4 in assessing
the risk of HCC development, and the combined use of LS and FIB-4 did, MD, PhD, Jun Y , PhD,
D, Kijun Song, PhD, and Kwang-Hyub Han, MD
(Medicine 95(20):e3434)
Abbreviations: ALT = alanine aminotransferase, AST = aspartate
aminotransferase, AUROCs = areas under the ROC curves, CHB =
chronic hepatitis B, HBV = hepatitis B virus, HCC = hepatocellular
carcinoma, IQR = interquartile range, kPa = kilopascals, LS = liver
stiffness, ROC = receiver-operating characteristic, TE = transient
elastography.
INTRODUCTION
C hronic hepatitis B virus (HBV) infection is a major cause ofcirrhosis and hepatocellular carcinoma (HCC).1 Active
antiviral treatment using potent antivirals has improved long-
term prognoses by suppressing HBV replication, preventing
liver damage, inducing fibrosis regression, and eventually
reducing the risk of disease progression, including HCC devel-
opment.2,3 Nevertheless, the risk of HCC remains, because
advanced fibrosis or cirrhosis, which is the single most import-
ant risk factor for HCC, is not completely resolved by antiviral
treatment.3–5 Hence, aside from the suppression of HBV repli-
cation using antivirals, it is of paramount importance to assess
the degree of liver fibrosis and identify early compensated
cirrhosis in order to stratify long-term prognoses, assess
HCC risks, and optimize surveillance strategies for patients
with chronic hepatitis B (CHB).
Although histological assessment is the gold standard for
assessing the degree of liver fibrosis and cirrhosis, it is not
feasible in clinical practice to use liver biopsy as a screening
tool for patients with CHB. To date, several other noninvasive
imaging modalities have been used to assess the degree of liver
fibrosis.6–8 Among those, liver stiffness (LS) assessed using
transient elastography (TE) was recently demonstrated to be a
reliable and accurate noninvasive tool for assessing the degree
of liver fibrosis.9,10 Recent large-scale longitudinal studies also
showed a significant association between the LS value and the
risk of HCC development in patients with CHB.11,12 In addition,
various serologic biomarkers of liver fibrosis have been devel-
oped to stage the degree of liver fibrosis.8 Some biomarkers use
the serum concentration of specific components related to
fibrogenesis and fibrosis breakdown, whereas others are based
on simple serological markers derived from blood tests in
routine clinical practice reflecting liver function or portal
hypertension.8 Of these serologic biomarkers, FIB-4,13 an index
calculated from patient age, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and platelet count, has shown
strong diagnostic performance in assessing the degree of liverh clinical applicability, because it can
routine laboratory tests.14 In addition,
as proven to be a significant prognostic
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predictor of HCC development in patients with CHB and other
liver diseases.15,16
Because no comparative data have been available so far,
we aimed to compare the prognostic performance of LS as
measured by TE with that of FIB-4 in assessing the risk of HCC
development in patients with CHB. We also investigated
whether the prognostic performance could be enhanced when
TE and FIB-4 are combined.
MATERIALS AND METHODS
Patients
The study population of this retrospective study was based
upon that of our previous study, conducted to validate the
prognostic performance of several risk-prediction models for
HCC development.17 The inclusion criteria were as follows: (1)
chronic HBV infection and (2) available TE data. The exclusion
criteria were as follows: (1) unreliable LS values, (2) a history of
HCC or liver decompensation, (3) coinfection with hepatitis C
virus infection or other serious medical illness, and (4) an
insufficient follow-up time or HCC development within 6
months since enrollment. Finally, a total of 1308 patients were
enrolled for analysis.
This study was approved by the institutional review board
of Severance Hospital.
Clinical Evaluation and Follow-up
Patients were followed-up every 3 to 6 months with routine
laboratory tests. Furthermore, every 6 months, abdomen ultra-
sonography and serum a-fetoprotein were performed for
HCC surveillance.
Diagnosis of Liver Cirrhosis and HCC
Diagnosis of liver cirrhosis was made by histological or
clinical evaluation. In case that histological data were not
available, liver cirrhosis was diagnosed clinically when one
of the following criteria was fulfilled:18 (1) platelet count
<100,000/mL and presence of ultrasonographic features such
as a blunted, nodular liver edge accompanied by splenomegaly
(>12 cm); or (2) evidence of portal hypertension.12 Diagnosis of
HCC was made by either histological or radiological evaluation
on the basis of the guidelines of the American Association for
the Study of Liver Diseases.19
LS and FIB-4 Assessments
LS was measured using TE (FibroScan, EchoSens, Paris,
France), performed by a single experienced technician blinded
to the clinical and biochemical data of the patients. Fibroscan
502 with M probe had been applied until March 2013, and
thereafter, Fibroscan 502 Touch with M probe was used. The
principles of LS measurement were described previously.20
Only LS values with 10 valid measurements, a success rate
60%, and an interquartile range (IQR)-to-median ratio <30%
were considered reliable. The LS was expressed in kilopascals
(kPa). FIB-4 was assessed based on the laboratory parameters at
the time of enrollment as follows: FIB-4¼ age (years)AST
(U/L) / (platelets [109/L] [ALT {U/L}]1/2).13
Statistical Analyses
Kim et alWhen HCC occurred during the follow-up, the time to
HCC development was calculated as the interval between the
date of study entry and the date of HCC diagnosis. When HCC
2 | www.md-journal.comdid not occur during the follow-up, it was calculated as the
interval between the date of study entry and the date of last
follow-up. Patients with follow-up duration of >7 years were
censored at 7 years. The cumulative rate of HCC development
was analyzed using the Kaplan–Meier method with compari-
sons by the log-rank test.
To evaluate the predictive values of FIB-4 and LS across
the entire follow-up period of 7 years, we applied a time-
dependent receiver-operating characteristic (ROC) curve
method for censored survival data. Then, we compared the
global concordance probability (expressed as the area under the
ROC curve [AUROC]) of the models using LS and FIB-4,
respectively. A greater AUROC indicates better predictive
performance. The differences in the AUROC between the LS
and FIB-4 models were tested using a bootstrap resampling
method.21 In addition, we stratified the study population using
cutoff values of LS (<8, 8–13, 13–18, 18–23, and >23 kPa)
and FIB-4 (<1.25, 1.25–1.70, 1.70–24.0, and>2.40) defined in
previous studies12,15 to compare the prognostic performances of
LS and FIB-4 in the setting of categorical stratification.
All statistical procedures were conducted using SAS soft-
ware version 9.2 (SAS Institute) and R software version 3.1.1
(http://cran.r-project.org/). A P value <0.05 was considered
statistically significant.
RESULTS
Baseline Characteristics
The baseline characteristics of the study population
(n¼ 1308) are summarized in Table 1. The mean age of the
entire study population (883 men and 425 women) was 50 years.
Liver cirrhosis was identified in 233 (17.8%) patients. HBeAg
was positive in 519 (39.7%) patients. Overall, 848 patients
(64.8%) experienced antiviral therapy; 434 patients had
previous or ongoing use of antiviral agents at enrollment and
414 received antiviral therapy starting after enrollment. The
mean FIB-4 and LS values were 2.22 and 11.3 kPa, respectively.
HCC Development During the 7-year Follow-Up
The median follow-up duration was 6.1 (IQR: 4.1–6.9)
years. During the 7-year follow-up (the sum of the follow-up
duration of each patient: 7068.74 person-years), 119 patients
developed HCC. The cumulative incidence of HCC at 3, 5, and
7 years was 5.09%, 8.70%, and 11.03%, respectively. When the
study population was stratified according to the presence of
liver cirrhosis, the cumulative incidence of HCC at 3, 5, and 7
years was 3.68%, 6.33%, and 8.52%, respectively, in patients
without liver cirrhosis and 11.90%, 20.25%, and 23.28%,
respectively, in patients with liver cirrhosis.
Cumulative Incidence of HCC According to
Stratified LS and FIB-4 Values
The cumulative incidence of HCC during the 7-year
follow-up according to the stratified LS and FIB-4 values is
depicted in Figure 1A and B. The respective cumulative inci-
dences of HCC at 3, 5, and 7 years were 1.09%, 2.40%, and
4.03%, respectively, in patients with LS8 kPa; 4.57%, 8.60%,
and 12.72% in patients with 8 kPa<LS13 kPa; 7.93%,
15.05%, and 17.82% in patients with 13 kPa<LS18 kPa;
Medicine  Volume 95, Number 20, May 201616.80%, 22.94%, and 22.94% in patients with 18 kPa<LS23
kPa; and 19.98%, 32.24%, and 34.95% in patients with LS>23
kPa. The cumulative incidence of HCC increased in a step-wise
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of the Study Population
(n¼1308)
Variable Values
Age, years 50 10
Male gender 883 (67.5)
Body mass index, kg/m2 23.4 2.7
Alanine aminotransferase, IU/L 40.7 28.2
40 IU/L 835 (63.8)
>40 IU/L 473 (36.2)
Total bilirubin, mg/dL 0.9 0.4
Prothrombin time, INR 1.03 0.16
Platelet count, 109/L 161 56
Alpha-fetoprotein, ng/mL 6.34 12.22
HBeAg positivity 519 (39.7)
Liver cirrhosis 233 (17.8)
FIB-4 2.22 1.92
<1.25 394 (30.1)
1.25–1.69 266 (20.3)
1.70–2.39 263 (20.1)
2.4 385 (29.5)
LS value, kPa 11.3 11.5
8 kPa 659 (50.4)
8.1–13 kPa 316 (24.2)
13.1–18 kPa 166 (12.7)
18.1–23 kPa 60 (4.6)
>23 kPa 107 (8.1)
Variables are expressed as meanSD or n (%).
INR¼ international normalized ratio, kPa¼ kilopascal, LS¼ liver
Medicine  Volume 95, Number 20, May 2016manner among the 5 groups (log-rank test, all P< 0.05 between
the 2 adjacent curves; Figure 1A).
The respective cumulative incidences of HCC at 3, 5, and 7
years were 1.31%, 2.23%, and 4.26%, respectively, in patients
stiffness.with FIB-4<1.25; 1.53%, 1.53%, and 2.03% in patients with
1.25 FIB-4<1.70; 4.98%, 9.55%, and 12.29% in patients with
1.70 FIB-4<2.40; and 11.45%, 19.82%, and 23.44% in
FIGURE 1. Cumulative development of HCC according to stratified LS
increased significantly in associationwith increased LS or FIB-4 values (lo
the Kaplan–Meier survival curve of patients with FIB-4<1.25 and those
HCC¼hepatocellular carcinoma, LS¼ liver stiffness.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.patients with FIB-42.40. The cumulative incidence of HCC
increased in a step-wise manner among 3 of the groups
(1.25FIB-4<1.70, 1.70FIB-4<2.40, and FIB-42.40; log-
rank test, all P<0.05 between the 2 adjacent curves). However,
the Kaplan–Meier curves of the patients with FIB-4<1.25 and
those with 1.25FIB-4<1.70 overlapped (log-rank test,
P¼ 0.445; Figure 1B).
Comparison of the Prognostic Performances of
LS and FIB-4 in Predicting HCC
The performances of LS and FIB-4 in predicting HCC
during 3-year, 5-year, and 7-year follow-up, as well as the
comparisons among them, are summarized in Table 2. During
the 7-year follow-up period, the AUROCs of LS ranged from
0.795 to 0.807, whereas those of FIB-4 ranged from 0.742 to
0.749. When the AUROCs of LS and FIB-4 were compared, LS
consistently showed significantly greater prognostic perform-
ance than FIB-4 (all P< 0.05). When the AUROCs of LS and
FIB-4 at every time point during the 7-year follow-up were
plotted, LS showed consistently better performance than FIB-4
after 1 year of enrollment (Figure 2).
The prognostic performances of LS and FIB-4 were also
compared among subgroups stratified according to antiviral
treatment status, ALT level, and fibrotic burden, which can
influence the accuracy of TE (Table 3). In the subgroups with
antiviral treatment at enrollment (n¼ 848, 64.8%), normal ALT
level (40 IU/L, n¼ 835, 63.8%), and liver cirrhosis (n¼ 221,
16.9%), LS showed significantly (P< 0.05) better performance
than FIB-4 in predicting HCC development over 3 years
(AUROC: 0.772 vs 0.723, 0.833 vs 0.719, and 0.755 vs
0.607, respectively), 5 years (AUROC: 0.780 vs 0.728, 0.830
vs 0.756, and 0.730 vs 0.619, respectively), and 7 years
(AUROC: 0.774 vs 0.722, 0.826 vs 0.759, and 0.713 vs
0.616, respectively).
In addition, when LS and FIB-4 were processed as categ-
orical scales using predefined cutoffs (<8 kPa, 8–13 kPa, 13–
18 kPa, 18–23 kPa, and >23 kPa for LS12 and <1.25, 1.25–
1.70, 1.70–24.0, and >2.40 for FIB-415), LS showed signifi-
cantly better performance than FIB-4 in predicting HCC devel-
Liver Stiffness versus FIB-4 for Prognosis Predictionopment within 3 years or 5 years (all P< 0.05). The difference
was marginal, however, in terms of predicting HCC develop-
ment within 7 years (P¼ 0.075; Table 4).
(A) and FIB-4 (B) value. The cumulative rate of HCC development
g-rank test; allP<0.05 between the 2 adjacent curves). However,
with FIB-41.25 and<1.70 overlapped (log-rank test,P¼0.445).
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TABLE 2. Performances of LS and FIB-4 to Predict HCC Development During 7-Year Follow-Up and Their Comparisons
LS FIB-4
Follow-up Duration AUROC
95% CI
AUROC
95% CI
P ValueLower Limit Upper Limit Lower Limit Upper Limit
3-year 0.807 0.767 0.846 0.743 0.707 0.787 0.028
5-year 0.807 0.767 0.836 0.749 0.725 0.782 0.012
7-year 0.795 0.760 0.830 0.742 0.708 0.778 0.037
den
Kim et al Medicine  Volume 95, Number 20, May 2016The Prognostic Performance of the combined
use of LS and FIB-4
Although LS was superior to FIB-4 in predicting HCC
development, both tests showed acceptable performance
(AUROC approximately 0.75). We investigated whether
the prognostic performance could be enhanced when LS and
FIB-4 were simultaneously entered into the equation. When LS
and FIB-4 were simultaneously used in a continuous manner to
predict HCC development during the 7-year follow-up, and
when combined performance was compared with that of using
LS or FIB-4 alone, the AUROC of the combined values was
similar to that of LS (AUROC: 0.814 [95% CI: 0.777–0.850] vs
0.795 [95% CI: 0.760–0.830], P¼ 0.469), but significantly
greater than that of FIB-4 (AUROC: 0.752 [95% CI: 0.718–
0.788], P¼ 0.018; Supplementary Table 1, http://links.lww.
com/MD/A902). Similar results occurred when stratified LS
and FIB-4 using previously defined cutoff values were entered
into the equation (AUROC: 0.794 [95% CI: 0.754–0.837] for
the combined stratified values vs 0.773 [95% CI: 0.731–0.814]
AUC¼ area under receiver operating characteristic curve, CI¼ confifor the stratified LS only [P¼ 0.481] and 0.731 [95% CI:
0.691–0.770] for the stratified FIB-4 only [P¼ 0.031]; Supple-
mentary Table 1, http://links.lww.com/MD/A902).
FIGURE 2. Time-dependent ROC curve analyses during 7-year
follow-up. The AUROC of LS is consistently higher than that of
FIB-4 after 1 year of enrollment. AUROC¼ area under
receiver operating characteristic curve, LS¼ liver stiffness,
ROC¼ receiver-operating characteristic.
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In this study, LS assessed using TE was consistently
superior to FIB-4 in predicting HCC development at each time
point during the 7-year follow-up period, although both tests
could estimate the risk of developing HCC and stratify prog-
noses among subgroups of patients with CHB. We acknowledge
that FIB-4 is calculated using age, AST, ALT, and platelet
count, which are obtained during routine clinical practice;
therefore, FIB-4 can be useful for assessing the risk of HCC
because of its minimal cost, easy applicability, and considerable
diagnostic performance, especially when TE is not available.
Nevertheless, our results suggest that LS should be favored to
improve prognostication in present HCC surveillance strategies
for patients with CHB, as far as resources permit.12
Recently, several Asian studies have investigated the
prognostic role of LS in the noninvasive assessment of the risk
for CHB-related HCC development.12,22–24 In a large Korean
prospective cohort study that enrolled 1130 patients with CHB,
stratified LS was identified as 1 independent risk factor for HCC
development, with a relative risk of 3.07, 4.68, 5.55, and 6.60
for LS of 8–13, 13–19, 18–23, and >23 kPa, respectively,
compared with LS< 8 kPa as a reference.12 Another study from
Hong Kong,22 in which 528 patients with HBeAg-negative
CHB were followed up, showed that the cumulative incidence
of HCC was higher in patients with LS 10 kPa compared with
those with LS< 10 kPa (9% vs 0%, respectively; P< 0.001). A
multivariate analysis showed that only LS was significantly
associated with HCC development. Furthermore, it was
reported that TE can identify patients with CHB and subclinical
cirrhosis that are at increased risk for developing HCC.18 Based
on the prognostic role of TE, the prognostic efficacies of
conventional HCC prediction models, such as REACH-B and
CU-HCC score, might be improved by incorporating the LS
values to generate modified REACH-B11 and LSM-HCC
models.25 Our results, along with those of numerous previous
studies, all support the prognostic role of TE in predicting HCC
development in patients with CHB, most likely because a wide,
continuous, dynamic range of up to 75 kPa is applied to evaluate
the degree of liver fibrosis. Consequently, more detailed prog-
nostication is allowed not only for patients with clinical cir-
rhosis, but also for patients without overt clinical evidence of
cirrhosis. Although use of LS has become more and more
popular worldwide, the issue of its limited use due to the high
cost of TE remains.
FIB-4, in conjunction with LS, might be regarded as one of
acceptable noninvasive methods for evaluating the degree of
ce interval, LS¼ liver stiffness.fibrosis. However, in terms of the performance for noninvasive
prediction of liver fibrosis, FIB-4 does not surpass LS.26,27 As a
matter of fact, FIB-4 only provides the moderate degree of
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
enrolled a relatively large number of patients with CHB
TABLE 3. Subgroup Analysis According to Antiviral Treatment Status, ALT Level, and Fibrotic Burden
LS FIB-4
Follow-up Duration AUROC
95% CI
AUROC
95% CI
P ValueLower Limit Upper Limit Lower Limit Upper Limit
With antiviral treatment (n¼ 848, 64.8%)
3-year 0.772 0.740 0.801 0.723 0.689 0.762 0.046
5-year 0.780 0.746 0.814 0.728 0.696 0.757 0.026
7-year 0.774 0.738 0.806 0.722 0.687 0.756 0.033
Normal ALT level (40 IU/L) (n¼ 835, 63.8%)
3-year 0.833 0.774 0.892 0.719 0.632 0.806 0.032
5-year 0.830 0.786 0.874 0.756 0.693 0.808 0.043
7-year 0.826 0.772 0.847 0.759 0.712 0.806 0.030
Liver cirrhosis (n¼ 221, 16.9%)
3-year 0.755 0.674 0.835 0.607 0.511 0.703 0.021
5-year 0.730 0.657 0.773 0.619 0.540 0.698 0.027
7-year 0.713 0.661 0.765 0.616 0.540 0.692 0.039
ratin
Medicine  Volume 95, Number 20, May 2016 Liver Stiffness versus FIB-4 for Prognosis Predictiondiagnostic value comparable to that of aspartate aminotransfer-
ase-to-platelet ratio index (APRI).28 Nevertheless, FIB-4 has
important advantages of good availability and cost-effectiveness
as APRI which has recently been recommended in resource-
limited settings as a screening tool for the underlying fibrotic
burden in patients with CHB according to the WHO guideline.29
Furthermore, similar to LS, FIB-4 has been evaluated with regard
to its longitudinal perspective to predict the development of HCC
and other prognostic outcomes.15,30–32 In our study, stratification
by LS was more appropriate for detailed prognostication than
stratification by FIB-4, which resulted in the overlap of the
Kaplan–Meier curves for the subgroups with FIB-4< 1.25 and
1.25FIB-4<1.70, respectively. That phenomenon was also
observed in an investigation by Suh et al,15 suggesting that
FIB-4 has the limited capability in differentiating the risk of
HCC development among patients in the early stages of disease in
contrast to LS. In addition, LS was consistently superior to FIB-4
in predicting HCC development at each time point during the 7-
ALT¼ alanine aminotransferase, AUROC¼ area under receiver opeyear follow-up period. We can, therefore, cautiously speculate
that TE might have significant clinical merit in stratifying patients
with CHB into those who would or would not benefit from regular
TABLE 4. Performances of Stratified LS and FIB-4 Using Predefine
Follow-Up and Their Comparisons
LS
Follow-up Duration AUROC
95% CI
Lower Limit Upper Lim
3-year 0.798 0.747 0.842
5-year 0.787 0.743 0.821
7-year 0.783 0.741 0.824
AUC¼ area under receiver operating characteristic curve, CI¼ confiden
Predefined cutoff values

of LS (8 kPa, 13 kPa, 18 kPa, 23 kPa) and FI
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.HCC surveillance, and in designing more individualized surveil-
lance strategies. When LS and FIB-4 were simultaneously used to
predict prognosis, no additional benefit was observed compared
with the use of LS alone.
To the best of our knowledge, this is the first study to
directly compare the prognostic performances of LS and FIB-4
in predicting HCC development in patients with CHB. If the
prognostic performance of FIB-4 was comparable to that of LS,
the rationale to use TE for the aim of predicting HCC could be
challenged, especially in terms of cost-effectiveness. Because
LS has a more reliable predictive capacity compared with FIB-4
based on our study, it is reasonable to argue that LS should be
recommended as the primary tool for first assessment of the
fibrotic burden, and consequently for providing future prog-
nosis in routine clinical practice. Thereafter, FIB-4 might be
suggested as an alternative method especially when the resource
is limited. Another strength of our study is that we consecutively
g characteristic curve, CI¼ confidence interval, LS¼ liver stiffness.(n> 1300) from a single center with long-term follow-up (up
to 7 years), providing statistical power and reliability.
d Cutoff Values

to Predict HCC Development During 7-Year
FIB-4
AUROC
95% CI
P Valueit Lower Limit Upper Limit
0.727 0.676 0.772 0.040
0.726 0.694 0.758 0.019
0.731 0.691 0.770 0.075
ce interval, LS¼ liver stiffness.
B-4 (1.25, 1.70, and 2.40).
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In subgroups that included patients with antiviral therapy,
as well as those with normal serum ALT levels, LS had
significantly better prognostic performance compared with
FIB-4. In the current era of potent antiviral therapies, most
treated patients can eventually get positive virological and
biochemical responses through the use of antiviral
therapy.33–36 As necro-inflammation resolves either naturally
or through antiviral therapy, the effect of serum AST or ALT
levels on the disease progression also diminishes. That is one of
the reasons why the prognostic performance of FIB-4, which
includes AST and ALT as constituent variables, might be
suboptimal in those 2 subgroups. In addition, in subgroups with
liver cirrhosis, LS showed better performance than FIB-4,
suggesting that LS, which has a wide, continuous dynamic
range of up to 75 kPa, might have advantage over FIB-4 in
predicting prognoses.
Several issues remain unresolved in our study. First, the
study cohort consisted only of patients from a single tertiary
center, which might have limited generalizability to the entire
spectrum of patients with chronic HBV infection and to popu-
lations in other regions. Hence, further studies are required with
a community-based cohort to resolve those issues, and external
validation will be necessary to significantly enhance the value
of our study. Second, if data from liver biopsy, the gold-
standard test for liver fibrosis, had been available for all the
patients, more comprehensive conclusions might have been
drawn. However, liver biopsy for the sole purpose of estimating
the fibrotic burden for screening, might often be unavailable,
primarily because of its invasiveness.
In conclusion, LS assessed using TE showed signifi-
cantly greater prognostic performance than FIB-4 in predict-
ing the development of HBV-related HCC. The combined use
of LS and FIB-4 did not provide additional benefit compared
with the use of LS alone. Hence, LS assessment using TE
might be favored for the improvement of current HCC sur-
veillance strategies, as far as resources permit. Future studies
of larger and diversified populations are required to validate
our results.
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